Promising combo for tough lymphoma hits early hurdle
NCT ID NCT05618366
First seen Apr 05, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This early-phase trial tested a combination of two drugs, tazemetostat and venetoclax, in people with Non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goals were to find the safest dose and understand side effects. Only 3 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine/NewYork-Presberteryian Hospital
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.